LindaDianaBossermanMDPhD, AASECT, FACP, FASCO(She/Her)

PubMed

• 1 citations
  UGT1A1*28 polymorphism and the risk of toxicity and disease progression in patients with breast cancer receiving sacituzumab govitecan.
  Megan H Wong, Veronica C Jones, Wai Yu, Linda D Bosserman, Sayeh M Lavasani
  Cancer Medicine. 2024-08-01
• 1 citations
  Race and Ethnicity Representation in Phase 2/3 Oncology Clinical Trial Publications: A Systematic Review.
  Kekoa Taparra, Ryan Benavente, Jonathan J Shih, Megan Y Gimmen, Paul Tominez
  JAMA Health Forum. 2024-06-07
• 4 citations
  Pyramidal Decision Support Framework Leverages Subspecialty Expertise across Enterprise to Achieve Superior Cancer Outcomes and Personalized, Precision Care Plans.
  Linda D Bosserman, Isa Mambetsariev, Colton Ladbury, Afsaneh Barzi, Deron Johnson
  Journal of Clinical Medicine. 2022-11-14

Journal Articles

• American Society of Clinical Oncology Criteria for High-Quality Clinical Pathways in Oncology  
  Robin T. Zon, Stephen B. Edge, Ray D. Page, James N. Frame, Gary H. Lyman, James L. Omel, Dana S. Wollins, Sybil R. Green, and Linda D. Bosserman, Journal of Oncology Practice, 1/1/2017
• Value-based Medicine and Integration of Tumor Biology  
  Brooks GA, Bosserman LD, Mambetsariev I, Salgia R, Am Soc Clin Oncol Educ Book, 1/1/2017
• Deconstructing MACRA: the switch from volume- to value-based payment  
  Linda Bosserman, MD, interviewer co-author, Robin Zon, MD interviewee co-author, Journal of Community and Supportive Oncology, 1/1/2016
• Letter from the Editor: Pathways, processes, team work: paving the way for value-based care  
  Linda D Bosserman, MD, FACP, Journal of Community and Supportive Oncology, 1/1/2016
• American Society of Clinical Oncology Policy Statement on Clinical Pathways in Oncology  
  Robin T. Zon, James N. Frame, Michael N. Neuss, Ray D. Page, Dana S. Wollins, Steven Stranne, and Linda D. Bosserman, Journal of Oncology Practice, 1/1/2016
• Letter from the Editor: Clinical, practice, and policy trends: a round-up and review of the 2016 oncology landscape  
  Bosserman LD, Journal of Community and Supportive Oncology, 1/1/2016
• TITAN: Phase III study of doxorubicin/cyclophosphamide (AC) followed by ixabepilone (Ixa) or paclitaxel (Pac) in early-stage, triple-negative breast cancer (TNBC)  
  Denise A. Yardley, Linda D. Bosserman, Mark Robert Keaton, et. al, Journal of Clinical Oncology, 1/1/2015
• Letter from the Editor: Changing oncology compliance standards: step 1 in re-valuing clinician workload for value-based cancer care  
  Linda D. Bosserman, MD, FACP, Journal of Community and Supportive Oncology, 1/1/2015
• Toolbox to Reduce Lumpectomy Reoperations and Improve Cosmetic Outcome in Breast Cancer Patients: The American Society of Breast Surgeons Consensus Conference  
  Landercasper J1, Attai D, Atisha D, Beitsch P, Bosserman L, et. al., Annals of Surgical Oncology, 1/1/2015
• Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase...  
  DA Yardley, LD Bosserman, JA O'Shaughnessy, DA Yardley, LD Bosserman, JA O'Shaughnessy, et. al., Breast Cancer Research and Treatment, 1/1/2015
• Letter from the Editor: Oncology 2015: New Therapies and New Transitions toward Value-based Cancer Care  
  Linda D. Bosserman, MD, FACP, Journal of Community and Supportive Oncology, 1/1/2015
• Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update  
  Lyman GH1, Temin S, Edge SB, Newman LA, Turner RR, Weaver DL, Benson AB 3rd, Bosserman LD, Burstein HJ, Cody H 3rd, Hayman J, Perkins CL, Podoloff DA, Giuliano AE, Journal of Clinical Oncology, 1/1/2014
• Letter from the Editor: Pooling knowledge to tailor an integrated delivery system  
  Linda D. Bosserman, MD, FACP, Journal of Community and Supportive Oncology, 1/1/2014
• Reply to IA Voutsadakis et al and A Goyal et al  
  Armando E. Giuliano, Linda D. Bosserman, Stephen B, et. al., Journal of Clinical Oncology, 1/1/2014
• Partnering with a Payer to Develop a Value-Based Medical Home Pilot: A West Coast Practice’s Experience  
  Linda D. Bosserman, MD; Diana Verrilli, and Wendy McNatt, Journal of Oncology Practice, 1/1/2012
• A Copay Foundation Assistance Support Program for Patients Receiving Intravenous Cancer Therapy  
  Swapnil P. Rajurkar, MD, Cary A. Presant, MD, FACP, Linda D. Bosserman, MD, FACP, and Wendy J. McNatt. Wilshire Oncology Medical Group, LaVerne, CA, Journal of Oncology Practice, 1/7/2011
• The Anemia Impact Measure (AIM): Development and Content Validation of a Patient-Reported Outcome Measure of Anemia Symptoms and Symptom Impacts in Cancer Patients Rec...  
  Leah Kleinman1, Katy Benjamin1, Hema Viswanathan2, Maria Stoeckl Mattera1, Linda Bosserman3, Douglas W. Blayney4, Dennis A. Revicki1. 1Outcomes Research, United BioSou..., Quality of Life Research, 1/1/2011
• American Society of Clinical Oncology Clinical Practice Guideline Update on the Role of Bone Modifying Agents in Metastatic Breast Cancer  
  Catherine Van Poznak, Sarah Temin, Gary Yee, Nora Janjan, William Barlow, J. Sybil Biermann, Linda Bosserman, Cindy Geoghegan, Bruce Hillner, Richard Theriault, Dan Zu..., Journal of Clinical Oncology, 1/1/2011
• Zoledronic Acid Effectively Prevents Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST Stu...  
  Adam M. Brufsky, MD, PhDa; Linda D. Bosserman, MDb; Richard R. Caradonna, MDc; Barbara B. Haley, MDd; C. Michael Jones, MDe; Halle C.F. Moore, MDf; Lixian Jin, MDg; Gh..., Clinical Breast Cancer, 1/1/2009
• A Phase I/II Trial of Trastuzumab plus Erlotinib in Metastatic HER2-Positive Breast Cancer: A Dual ErbB Targeted Approach  
  Carolyn D. Britten,1 Richard S. Finn,1 Linda D. Bosserman,2 Steven G. Wong,1 Michael F. Press,3 Mubashira Malik,4 Bert L. Lum,4 Dennis J. Slamon.1 1Jonsson Comprehens..., Clinical Breast Cancer, 1/1/2009
• Letter from the Editor: Rational care is not rationing  
  Linda D. Bosserman, MD, FACP, Community Oncology, 1/1/2009
• A community oncology quality initiative: guideline adherence with adjuvant hormonal therapy in women more than or equal to 45 with stage IB-IIIC hormone-sensitive brea...  
  Linda D. Bosserman, MD, FACP,1 Tracie Vanderpool, BA,1 Nikhil Bassi, BA,1 Brandon Emilio, BA,1 Azah B. Borham, PharmD,2 Zhixiao Wang, PhD,3 and Connie Chen, PharmD,3. ..., Community Oncology, 1/1/2009
• Letter from the Editor: Data and cancer care: play or pay  
  Linda D. Bosserman, MD, FACP, Community Oncology, 1/1/2009
• Is Your Practice Getting the Most from its EHR? The Wilshire Oncology Medical Group Experience  
  Cary A. Presant, MD, FACP; Linda Bosserman, MD, FACP; Wendy McNatt; and Brandon Emilio, Oncology Issues, 1/1/2009
• Implementing EHRs in Community Oncology Practices  
  Cary A. Presant, MD, FACP; Linda Bosserman, MD, FACP; Wendy McNatt; and Brandon Emilio, Oncology Issues, 1/1/2009
• Join now to see all

Abstracts/Posters

• Risk of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) after adjuvant chemotherapy (CT) for early breast cancer (BC) in the community setting.
  Neelima Denduluri, Janet L. Esposito, Brian Turnwald, Yunfei Wang, Lina Asmar, J. Russell Hoverman, Marcus A. Neubaue, Linda D. Bosserman, Leslie T. Busby, Barry Don ..., J Clin Oncol; ASCO Breast Cancer Symposium, 1/1/2012
• Efficacy and Safety of Ixabepilone + Capecitabine in Elderly Patients with Anthracycline and Taxane Pretreated Metastatic Breast Cancer.
  Vahdat L,1 Vrodljak E,2 Gomez H,3 Li RK,4 ThomasE,5 Bosserman L,6 Sparano JA,7 Baselga J,8 Mukhopadhyaya P,9 Valero A10. 1Weill Cornell Medical College, New York, NY;..., American Geriatrics Society Annual Scientific Meeting, 1/1/2012
• Phase II Study Evaluating Lapatinib in Combination With nab-Paclitaxel in Women Who Have Received less than or equal to 1 Chemotherapy Regimen for HER2-Overexpressing ...
  Denise A. Yardley 1,2, Lowell Hart3, Linda Bosserman4, Mansoor N. Saleh5, David M. Waterhouse6, Maura K. Hagan7, Paul Richards8, Michelle L. DeSilvio9, Janine M. Mahon..., San Antonio Breast Cancer Symposium, 1/1/2011
• Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline and taxane pretreated metastatic breast cancer.
  L. T. Vahdat, E. Vrdoljak, H. Gomez, R. K. Li, E. Thomas, L. D. Bosserman, J. A. Sparano, J. Baselga, P. Mukhopadhyay, V. Valero; Weill Cornell Medical College, New Yo..., ASCO Annual Meeting, 1/1/2011
• Disease Free Survival (DFS), Overall Survival (OS) and Evidence Based Guideline (EBG) Compliance With Adjuvant Trastuzumab Therapy in HER2-positive (HER2+) Early Breas...
  Bosserman LB, MD, FACP,1 Upadhyaya G, MD, FACP,1 Chernick M, PhD,2 Iyer S, Phd,3 Vanderpool T,1 Emilio B,1 and Presant CA, MD, FACP1. 1Wilshire Oncology Medical Group..., San Antonio Breast Cancer Symposium, 1/1/2011
• A Randomized, Double-Blind, Placebo-Controlled Trials of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients with HER2-Negative Metast...
  Denise A. Yardley MD1,2, Joyce O'Shaughnessy MD3, Linda Bosserman MD4, Anne Favret MD5, William Harwin MD6, Michael Juzur MD2, Susan Morgan MD6, Nancy Peacock MD2, Vic..., San Antonio Breast Cancer Symposium, 1/1/2011
• Maintenance of Clinical Efficacy Following Dose Reduction of Ixabepilone plus Capecitabine in Patients with Anthracycline and Taxane Pretreated Metastatic Breast Cance...
  V. Valero, L. D. Bosserman, D. A. Yardley, H. H. Roche, E. Thomas, L. T. Vahdat, P. Mukhopadhyaya, D. M. M. Opatt, R. A. Peck, J. Sparano; The University of Texas, M.D..., ASCO Annual Meeting, Chicago, IL, 1/1/2010
• Resource utilization requirements for personalized cancer care translational research and clinical trial (CT) implementation.
  S. P. Rajurkar, C. A. Presant, G. H. Upadhyaya, L. D. Bosserman, B. Ebrahimi, F. D. Howard, S. W. Kim, R. C. Horns, D. Malouf; Wilshire Oncology Medical Group, Inc., L..., ASCO Annual Meeting, 1/1/2010
• Phase II Trial of Presurgical Treatment with Trastuzumab (H) or Lapatinib (Ty) or the Combination of Trastuzumab and Lapatinib (H+Ty), Followed by Six Cycles of Doceta...
  R. Callahan, D. Slamon, R. Patel, D. Chan, M. Allison, B. Dicarlo, L. Bosserman, A. Kennedy, L.M. Zehngebot, J. Miller, A.E. Giuliano, L.S. Lin, S.A. Hurvitz, San Antonio Breast Conference, 1/1/2010
• A 5-year report on Bone-specific alkaline phosphatase (BSAP) and serum N-telopeptide (sNTX) as predictors of bone loss in postmenopausal women with early breast cancer...
  Brufsky A, Vogel C, Seidler C, Bosserman L, Jin L, Warsi G, Argonza-Aviles E, Ericson S, Perez EA. University of Pittsburgh Cancer Institute, Pittsburgh, PA; Comprehe..., IX International Meeting on Cancer Induced Bone Disease, Arlington, VA, 1/1/2009
• A Novel Co-pay Foundation Assistance Support Program for Patients Receiving IV Cancer Therapy in Cancer Centers.
  Swapnil Rajurkar, Cary Presant, Linda Bosserman, Wendy McNatt, 45th ASCO Annual Meeting, Orlando, FL, 1/1/2009
• Denosumab Treatment of Prostate Cancer With Bone Metastases And Elevated Urine N-Telopeptide Levels After Therapy With Intravenous Bisphosphonates: Results Of A Phase ...
  Karim Fizazi, 1 Linda Bosserman, 2 Guozhi Gao, 3 Tomas Skacel, 4 Carsten Goessl. 3 1Intitut Gustave Roussy, Villejuif, France; 2Wilshire Oncology Medical Group, La Ver..., Genitourinary Cancers Symposium, Orlando, FL, 1/1/2009
• A Quality Initiative: Guideline Compliance in Postmenopausal Women With Stage IB-IIIC Early Breast Cancer Receiving Adjuvant Hormonal Therapy.
  Linda D. Bosserman, MD, FACP,1 Tracie Vanderpool, 1 Nikhil Bassi, 1 Brandon Emilio, 1 Azah B. Borham, PharmD, 2 Zhixiao Wang, PhD, 3 Connie Chen, PharmD3 1Wilshire Onc..., St. Gallen Oncology Conference, St. Gallen, Switzerland, 1/1/2009
• Safety results of lapatinib combined with nab-Paclitaxel in women with 1st or 2nd line HER2 overexpressing metastatic breast cancer (MBC).
  D. A. Yardley, R. C. Whorf, L. D. Bosserman, M. N. Saleh, D. M. Waterhouse, S. Lahiri, J. M. Mahoney, P. D. Richards; Sarah Cannon Research Institute, LLC, Nashville, ..., ASCO Breast Cancer Symposium, 1/1/2009
• Zoledronic acid prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer: 36-month follow-up of the Z-FAST study.
  Brufsky A, Bosserman L, Caradonna R, Haley B, Jones M, Moore H, Dong M, Warsi G, Lacerna L, Perez E. on behalf of the Z-FAST Study Group, European Breast Cancer Conference, 1/1/2008
• Patterns of metastatic (met) disease sites in breast cancer (BrCa): implications for availability of fresh tumor tissue (FTT) for personalized BrCa treatment (Rx) plan...
  Cary A. Presant, Linda Bosserman, Frank Howard and Brandon Emilio, Wilshire Oncology Medical Group, La Verne, California, Amer Soc Clin Oncol, 1/1/2008
• Denosumab Treatment of Prostate Cancer With Bone Metastases and Elevated Urine N-telopeptide Levels After Therapy With Intravenous Bisphosphonates: Results of a Phase ...
  Karim Fizazi, 1 Linda Bosserman, 2 Guozhi Gao, 3 Tomas Skacel, 4 Carsten Goessl. 3 1Intitut Gustave Roussy, Villejuif, France; 2Wilshire Oncology Medical Group, La Ver..., Society of Urologic Oncology Annual Meeting, 1/1/2008
• Denosumab in patients with bone metastases from castration-resistant prostate cancer and elevated bone resorption despite intravenous bisphosphonate (IV BP) therapy: a...
  Karim Fizazi, 1 Linda Bosserman, 2 Guozhi Gao, 3 Tomas Skacel, 4 Richard Markus. 3 1Intitut Gustave Roussy, Villejuif, France; 2Wilshire Oncology Medical Group, La Ver..., European Society for Medical Oncology, 1/1/2008
• A Multicenter Double-blind Randomized Phase 2 Trial of Neoadjuvant Treatment with Single-Agent Bevacizumab or Placebo, Followed by Docetaxel, Doxorubicin, and Cyclopho...
  SA Hurvitz, 1 L Bosserman, 2 B Leland-Jones, 3 M Thirwell, 3 M Allison, 4 Barstis, 1 D Molthrop, 5 E Quan, 6 G Upadhyaya, 2 D Slamon 1, Amer Soc Clin Oncol, 1/1/2008
• Vitamin D (vD) deficiency (def) in breast cancer (brca) patients (pts).
  C A Presant, L Bosserman. Wilshire Oncology Medical Group, West Covina, California, Amer Soc Clin Oncol, 1/1/2007
• Wilshire Oncology Medical Group, LaVerne, California. "Evaluating compliance (com) with hematology (H)-oncology (O) quality (Q) standards in a community based managed...
  L. Bosserman, C. Presant, A. Der, A. Estrella, A. Greenburg, G. Upadhyaya, M. Vakil, Amer Soc Clin Oncol, 1/1/2007
• Overhead costs (OC) associated with quality care (QOC) monitoring to ensure compliance with national treatment guidelines (TG).
  R. Vakil, L.D. Bosserman, C. Presant, W. McNatt, A. Der, A. Greenburg, A. Estrella, G. Upadhyaya, M. Vakil; Wilshire Onc Medcl Grp Inc, La Verne, California, Amer Soc Clin Oncol, 1/1/2007
• High prevalence of vitamin D deficiency or insufficiency in breast cancer patients.
  Cary A. Presant, M.D.1, Linda Bosserman, M.D. 1 and Maria Ampudia, PA-C1. 1Wilshire Oncology Medical Group, West Covina, CA, United States, 91790-3961, 30th Annual San Antonio Breast Cancer Symposium, 1/1/2007
• Effects of Denosumab on Urine N-telopeptide Levels in Patients With Prostate Cancer Bone Metastases After Receiving Zoledronic Acid: Results from a Phase 2, Randomized...
  Fizazi, K.1, Bosserman, L.2, Lipton, A.3, Rahim, Y.4, Suarez, T.5, Mariette, X.6, Fan, M.7, Wu, L.8, Watt, M.9, Markus, R.8 1Insitut Gustave Roussy, Hematology, Ville..., 1st European Multidisciplinary Meeting on Urological Cancers, 1/1/2007
• Randomized Trial of Denosumab Versus Zoledronic Acid Prostate Cancer Patients With Bone Metastases and Elevated Bone Turnover Markers After Receiving Zoledronic Acid T...
  L Bosserman, Annual Meeting of the American Urological Association Education and Research, Inc, 1/1/2007
• Join now to see all

Lectures

• American Society of Clinical Oncology (ASCO): 2012 Cancer Center Business Summit 
  American Society of Clinical Oncology(ASCO), Fort Worth, Texas - 10/11/2012
• Integrating Practice Guidelines and EMR into Community Oncology Practice 
  Albuquerque, NM - 1/1/2008
• Integrating Clinical Guidelines into Practice 
  1/1/2008
• Delivering Cancer Care on Guidelines – Practical Steps for Oncology Practices and Initial Outcomes from Wilshire Oncology 
  1/1/2008
• Using Community Based Networks to Improve Quality 
  University of California, San Francisco - 1/1/2008
• Development of the Anemia Impact Measure (AIM): A Disease-specific Patient Reported Outcome (PRO) Instrument to Measure Anemia Symptoms and Their Impact on Functioning... 
  San Francisco, CA - 1/1/2008
• Enhancing Quality and Outcomes in Oncology Care: Transforming Our Delivery System 
  San Francisco, CA - 1/1/2008
• Improving Quality Care with Electronic Medical Records (EMR) & Clinical Pathways/Guidelines 
  San Francisco, CA - 1/1/2008
• A New Administration and a New Health Policy: What is the Impact on Your Patients and Your Practice? 
  San Francisco, CA - 1/1/2008
• EMR in Oncology: Documenting Quality Care 
  San Diego, CA - 1/1/2008
• The Power of Prevention: Women’s Cancer & Health 
  San Antonio Community Hospital, Upland, CA - 1/1/2008
• Integrating Clinical Pathways into Clinical Practice 
  Salinas, CA - 1/1/2008
• Integrating Clinical Pathways into Oncology Practice with Electronic Medical Records (EMR) 
  Rancho Mirage, CA - 1/1/2008
• Patient Centered Cancer Care 
  Rancho Cucamonga, CA - 1/1/2008
• EMRs, Quality Standards and Evidence Based Guidelines for Quality Cancer Care 
  Portland, OR - 1/1/2008
• Quality Cancer Care Through Guidelines and Partnering 
  Pomona, CA - 1/1/2008
• Treatment Protocol Guidelines & Quality Care from a Community Oncologist Perspective 
  Philadelphia, PA - 1/1/2008
• Understanding Hormone Therapy for Breast Cancer: Background, Mechanisms, Resistance and Clinical Trials 
  Los Angeles, CA - 1/1/2008
• Quality Care in Oncology: Measures and Evidence Based Treatment Protocols 
  Los Angeles, CA - 1/1/2008
• Improving Quality Cancer Care with Electronic Medical Records (EMR) 
  Brookfield, WI - 1/1/2008
• Implementing Clinical Guidelines in Community Practice 
  Brookfield, WI - 1/1/2008
• Integrating Quality Standards into Oncology Practice 
  San Francisco, CA - 1/1/2007
• Work and Your Cancer Treatment: A Doctor's Perspective 
  St. Joseph’s Hospital Cancer Center, Orange, CA - 1/1/2007
• Light of Hope - Honoring Those Touched by Breast Cancer 
  Robert and Beverly Lewis Family Cancer Care Center, Pomona, CA - 1/1/2005
• Breast Cancer: Medical Advances and Treatment 
  Fontana, CA - 1/1/2004
• Join now to see all

Other

• American Journal of Managed Care. A Discussion on Oncology Quality Tools: Filling in the Gaps 
  Bosserman L, Goldwater J, Malin J
  http://www.ajmc.com/journals/evidence-based-oncology/2016/June-2016
  1/1/2016
• Quantitative measurement of HER2 expression in breast cancers: comparison with 'real-world' routine HER2 testing in a multicenter Collaborative Biomarker Study and cor... 
  Denise A. Yardley, MP Bates, J Weidler, L Bosserman, et. al., doi:10.1186/s13058-015-0543-x
  1/1/2015
• VIDEO: Organizational Culture in the Oncology Medical Home: What Drives Success? 
  Patt D, Bosserman L
  http://www.medscape.org/viewarticle/837946
  1/1/2015
• VIDEO: Experts distill top clinical takeaways from breast cancer symposium. 
  Abraham J, Bosserman L, Patt D
  http://www.oncologypractice.com/home/article/video-experts-distill-top-clinical-takeaways-from-breast-cancer-symposium/eb16646b34e182750c009c3ec358d271.html
  1/1/2015
• Implementing EHRs in Community Oncology Practices. 
  Cary A. Presant, MD, FACP, Linda Bosserman, MD, FACP, Wendy McNatt, Brandon Emilio, CancerNetwork.com
  1/1/2011
• ASCO Clinical Practice Guideline Update on the Role of Bone-Modifying Agents in Metastatic Breast Cancer Slide Set (PPS) 
  Bosserman LD, Journal of Clinical Oncology
• ASCO VBCC-Wilshire Oncology Medical Home Pilot: Reengineering Cancer Care 
  Bosserman LD
  http://meetinglibrary.asco.org/content/87126?media=vm
• UC Berkley Innovation in Physician Payment and Organization for Cancer Care 
  Bosserman LD
  http://www.berkeleyhealthtech.org/resources/presentations.php
• Join now to see all